Ligufalimab is under clinical development by Akeso and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ligufalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ligufalimab is under development for the treatment of acute myeloid leukemia, myelodysplastic syndrome (MDS), relapsed or refractory advanced or metastatic solid tumors and non-Hodgkin lymphoma (NHL), head and neck cancer and gastrointestinal tumor, epithelial ovarian cancer, transitional cell cancer (urothelial cell cancer), metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, head and neck cancer squamous cell carcinoma, primary peritoneal cancer, fallopian tube cancer, hepatocellular carcinoma, cervical cancer, metastatic biliary tract cancer, intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, pancreatic ducts adenocarcinoma, gastric cancer, adenocarcinoma of the gastroesophageal junction, esophageal squamous cell carcinoma, urothelial carcinoma, colorectal adenocarcinoma, non-small cell lung cancer, metastatic colorectal cancer, small cell lung cancer, sarcoma, triple-negative breast cancer and oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer and recurrent or metastatic head And neck cancer squamous cell carcinoma. The drug candidate is a monoclonal antibody acts by targeting leukocyte surface antigen CD47. It is administered through intravenous drip route.
Akeso is a clinical-stage biopharmaceutical company that focus on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also provides kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Ligufalimab’s drug-specific PTSR and LoA scores, buy the report here.